SPARC reports Q2 and half-year losses, continues as 'going concern'

Sun Pharma Advanced Research Company Ltd. announced that its board of directors approved the unaudited standalone and consolidated financial results for the second quarter and half-year ended September 30, 2025, at a meeting held on November 10, 2025. The company has incurred cash losses in past quarters and in the current quarter, but its "Going Concern" status continues due to a support letter from its promoter group entity.

For the half-year ended September 30, 2025, SPARC reported a standalone net loss of INR 12,800 lakhs, with total revenue from operations at INR 1,750 lakhs. Consolidated results for the same period show a net loss of INR 12,772 lakhs, with revenue from operations at INR 1,750 lakhs. The company's only reportable business segment is 'Pharmaceutical Research and Development.'

The unaudited financial results, along with the limited review report issued by statutory auditors SRBC & CO LLP, have been uploaded to the company's website. Kajal Damania, company secretary and compliance officer, confirmed these details.